Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases.

Inclusion Criteria: * Crohn's disease: Patients in remission, with a stable type of pharmacological treatment over the past 3 months and a stable dosage during the last month. * Ulcerative colitis: Patients in remission, with a stable type of pharmacological treatment over the past 3 months and a stable dosage during the last month. * Hypertension: Patients with systolic blood pressure of 130-139 mmHg or diastolic blood pressure of 80-89 mmHg, who maintain blood pressure within these ranges through lifestyle modifications, without active symptoms (e.g., headaches, dizziness), and not receiving antihypertensive medication. * Anemia: Patients with hemoglobin \<12 g/dL, serum iron \<40 μg/dL, and ferritin \<15 ng/mL for women, and hemoglobin \<13 g/dL, serum iron \<40 μg/dL, and ferritin \<30 ng/mL for men. Absence of severe clinical consequences. Presence of fatigue, weakness, or dizziness, which is usually manageable. * Multiple sclerosis: Patients in remission, with a stable type of pharmacological treatment over the past 3 months and a stable dosage during the last month. Exclusion Criteria: * Pregnancy or breastfeeding * Current use of antibiotics or antibiotic use within the past month * Current use of other probiotic, prebiotic, or synbiotic supplements * Current use of iron and/or zinc supplements * Change in the type of therapeutic regimen (pharmacotherapy) within the past three months * Change in the dosage of the therapeutic regimen (pharmacotherapy) within the past month * Renal or hepatic disease * Inability to provide informed consent (including individuals \<18 years of age) * Insufficient understanding of the Greek language